(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 meeting session discussing the management of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) included a presentation by Dr. Ian Davis regarding the evidence for “triplet therapy”, specifically ADT + docetaxel + primary additional systemic therapy.

X